The biology behind why cannabis-based medicines work for MS spasticity
The endocannabinoid system plays a fundamental role in controlling neurotransmission disrupted in MS, providing the biological rationale for why cannabis-based medicines reduce spasticity.
Quick Facts
What This Study Found
This review connected the biology of MS to the biology of the endocannabinoid system, explaining why cannabis-based medicines work for spasticity at a fundamental level. MS damages myelin and impairs neurotransmission. Cannabinoid receptors and endocannabinoids naturally regulate neurotransmission, making them logical therapeutic targets.
The review traced the path from MS patients self-medicating with street cannabis, through preclinical validation in animal models of MS, to the approval of cannabis-based medicines. The endocannabinoid system was positioned not just as a symptomatic treatment target but as potentially relevant to the accumulation of progressive disability in MS.
Key Numbers
Cannabis-based medicines approved for pain and spasticity in MS at time of publication.
How They Did This
Review article connecting MS disease biology to endocannabinoid system biology. Integrated preclinical animal model data with clinical approval evidence for cannabis-based medicines.
Why This Research Matters
Understanding why cannabis-based medicines work, not just that they work, helps guide further drug development and identifies which patients might benefit most.
The Bigger Picture
The biological rationale reviewed here extended beyond symptom control. If the endocannabinoid system can influence disease progression through neuroprotection and regulation of neurotransmission, cannabinoid medicines could potentially address both symptoms and disease course.
What This Study Doesn't Tell Us
Review by authors in the field. The disease modification argument was largely preclinical. The biological rationale, while logical, does not guarantee clinical efficacy for all applications.
Questions This Raises
- ?Can endocannabinoid system biology predict which MS patients respond best to cannabinoid treatment?
- ?Do endocannabinoid levels change during MS progression?
- ?Could targeted cannabinoid therapies slow disability accumulation?
Trust & Context
- Key Stat:
- Endocannabinoid system directly controls neurotransmission disrupted in MS
- Evidence Grade:
- Review integrating basic science and clinical evidence. Provides a strong mechanistic framework but the disease modification argument was speculative.
- Study Age:
- Published in 2012. Cannabis-based medicines for MS are now widely approved and prescribed.
- Original Title:
- The biology that underpins the therapeutic potential of cannabis-based medicines for the control of spasticity in multiple sclerosis.
- Published In:
- Multiple sclerosis and related disorders, 1(2), 64-75 (2012)
- Authors:
- Baker, David(10), Pryce, Gareth(10), Jackson, Samuel J(4), Bolton, Chris, Giovannoni, Gavin
- Database ID:
- RTHC-00542
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
Why does cannabis help with MS spasticity?
MS damages the myelin that insulates nerve fibers, disrupting how signals travel in the brain and spinal cord. The endocannabinoid system naturally regulates these nerve signals. Cannabis-based medicines activate this system to help restore more normal signal transmission, reducing spasticity.
Could cannabis slow MS progression?
Preclinical evidence suggested possible anti-inflammatory and neuroprotective effects that could slow progression. However, this has not been convincingly demonstrated in human clinical trials.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-00542APA
Baker, David; Pryce, Gareth; Jackson, Samuel J; Bolton, Chris; Giovannoni, Gavin. (2012). The biology that underpins the therapeutic potential of cannabis-based medicines for the control of spasticity in multiple sclerosis.. Multiple sclerosis and related disorders, 1(2), 64-75. https://doi.org/10.1016/j.msard.2011.11.001
MLA
Baker, David, et al. "The biology that underpins the therapeutic potential of cannabis-based medicines for the control of spasticity in multiple sclerosis.." Multiple sclerosis and related disorders, 2012. https://doi.org/10.1016/j.msard.2011.11.001
RethinkTHC
RethinkTHC Research Database. "The biology that underpins the therapeutic potential of cann..." RTHC-00542. Retrieved from https://rethinkthc.com/research/baker-2012-the-biology-that-underpins
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.